<DOC>
	<DOCNO>NCT00485732</DOCNO>
	<brief_summary>Human papillomavirus infection clearly recognize cause cervical cancer . The infection cervix certain oncogenic type HPV , clear , lead cervical cancer woman . This study evaluate immunogenicity safety GSK Biologicals ' HPV-16/18 L1 VLP AS04 vaccine ( Cervarix TM ) vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>A Study Evaluate Immune Response Safety GSK Biologicals ' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine Healthy Females Aged 15-25 Years</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A female , include , 15 25 year age time first vaccination . Written inform assent obtain subject informed consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Subjects must negative urine pregnancy test . Subjects childbearing potential time study entry must abstinent , must use adequate contraceptive precaution 30 day prior vaccination must agree continue precaution two month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study/ control vaccine within 30 day precede first dose study/ control vaccine , plan use study period . Pregnant breastfeeding . Planning become pregnant likely become pregnant . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day first dose vaccine . However , administration routine vaccine 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . Previous administration component investigational vaccine Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . Any medically diagnose suspect immunodeficient condition HIV infection base medical history physical examination . History thrombocytopenia hemostatic disorder case study vaccine circumstance administer intramuscularly . History allergic disease , suspect allergy reaction likely exacerbate component study/control vaccine . Hypersensitivity latex . Known acute chronic , clinically significant neurologic , pulmonary , cardiovascular , hepatic renal functional abnormality , determine previous physical examination laboratory test . History chronic condition ( ) require treatment . Administration immunoglobulins and/or blood product within three month precede first dose study/control vaccine plan administration study period . Enrolment defer subject outside specify window . Acute disease time enrolment .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cervical neoplasia</keyword>
	<keyword>AS04</keyword>
	<keyword>Randomized</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>HPV-16/18 L1 VLP AS04</keyword>
	<keyword>Phase IIIb</keyword>
	<keyword>Korea</keyword>
	<keyword>HPV</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Controlled</keyword>
</DOC>